Compare Amphastar Pharmaceuticals Inc (AMPH) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Kohl's Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Kohl's Corporation trades at $16.87 (market cap $1.91B). The key difference: Kohl's Corporation is far larger — about 2.3× Amphastar Pharmaceuticals Inc's market cap, and Kohl's Corporation pays a 2.98% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KSS | |
|---|---|---|
Market Cap | $826.08M | $1.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $24.71 |
52-Week Low | $16.87 | $9.27 |
Enterprise Value | $1.22B | $8.01B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Kohl's (KSS) trades at $16.80, up 3.0% today, with a bearish technical signal and mixed fundamentals. Recent earnings have beaten expectations, with Q1 2026 showing early turnaround progress, but revenue has declined from $19.4B in 2022 to $16.2B in 2025. The stock is undervalued with a P/E of 7.06 and P/B of 0.47, while analyst sentiment is cautious with a consensus price target of $16.75.
The outlook hinges on Kohl's ability to stabilize sales through proprietary brands and cost controls, but risks include persistent revenue declines and competitive pressures. Upside potential exists if turnaround efforts gain traction, yet investor caution is warranted given weak technicals and mixed analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
